Nozuma S, Matsuzaki T, Tanaka M, Kodama D, Dozono M, Yoshida T
Int J Mol Sci. 2025; 26(4).
PMID: 40004169
PMC: 11855110.
DOI: 10.3390/ijms26041706.
Tanaka A, Ishitsuka Y, Ohta H, Takenouchi N, Nakagawa M, Koh K
PLoS Comput Biol. 2025; 21(1):e1012690.
PMID: 39746113
PMC: 11753684.
DOI: 10.1371/journal.pcbi.1012690.
Wang T, Hirons A, Doerflinger M, Morris K, Ledger S, Purcell D
Viruses. 2024; 16(10).
PMID: 39459949
PMC: 11512412.
DOI: 10.3390/v16101616.
Herrmann D, Meng S, Yang H, Mansky L, Saad J
Viruses. 2024; 16(10).
PMID: 39459862
PMC: 11512237.
DOI: 10.3390/v16101528.
Atani Z, Hosseini S, Goudarzi H, Faghihloo E
Glob Med Genet. 2024; 11(4):285-296.
PMID: 39224462
PMC: 11368560.
DOI: 10.1055/s-0044-1790210.
HLA-A*24 Increases the Risk of HTLV-1-Associated Myelopathy despite Reducing HTLV-1 Proviral Load.
Tanaka M, Takenouchi N, Arishima S, Matsuzaki T, Nozuma S, Matsuura E
Int J Mol Sci. 2024; 25(13).
PMID: 38999966
PMC: 11241684.
DOI: 10.3390/ijms25136858.
Co-Infections and Superinfections between HIV-1 and Other Human Viruses at the Cellular Level.
Acchioni C, Sandini S, Acchioni M, Sgarbanti M
Pathogens. 2024; 13(5).
PMID: 38787201
PMC: 11124504.
DOI: 10.3390/pathogens13050349.
Complete Rescue of HTLV-1 Infectivity by Depletion of Monocytes Together with NK and CD8 T Cells.
Gutowska A, Sarkis S, Rahman M, Goldfarbmuren K, Moles R, Bissa M
Pathogens. 2024; 13(4).
PMID: 38668247
PMC: 11054408.
DOI: 10.3390/pathogens13040292.
Comprehensive Insight into the Functional Roles of NK and NKT Cells in HTLV-1-Associated Diseases and Asymptomatic Carriers.
Mahdifar M, Boostani R, Taylor G, Rezaee S, Rafatpanah H
Mol Neurobiol. 2024; 61(10):7877-7889.
PMID: 38436833
DOI: 10.1007/s12035-024-03999-8.
Establishment of a novel human T-cell leukemia virus type 1 infection model using cell-free virus.
Nagata K, Tezuka K, Kuramitsu M, Fuchi N, Hasegawa Y, Hamaguchi I
J Virol. 2024; 98(2):e0186223.
PMID: 38294250
PMC: 10878273.
DOI: 10.1128/jvi.01862-23.
How Can We Prevent Mother-to-Child Transmission of HTLV-1?.
Itabashi K, Miyazawa T, Uchimaru K
Int J Mol Sci. 2023; 24(8).
PMID: 37108125
PMC: 10138424.
DOI: 10.3390/ijms24086961.
Advances in preventive vaccine development against HTLV-1 infection: A systematic review of the last 35 years.
Santana C, de Oliveira Andrade F, da Silva G, de Souza Nascimento J, Campos R, Giovanetti M
Front Immunol. 2023; 14:1073779.
PMID: 36860854
PMC: 9968880.
DOI: 10.3389/fimmu.2023.1073779.
HBZ upregulates myoferlin expression to facilitate HTLV-1 infection.
Polakowski N, Sarker M, Hoang K, Boateng G, Rushing A, Kendle W
PLoS Pathog. 2023; 19(2):e1011202.
PMID: 36827461
PMC: 9994761.
DOI: 10.1371/journal.ppat.1011202.
The PRMT5 inhibitor EPZ015666 is effective against HTLV-1-transformed T-cell lines and .
Ernzen K, Melvin C, Yu L, Phelps C, Niewiesk S, Green P
Front Microbiol. 2023; 14:1101544.
PMID: 36819050
PMC: 9932813.
DOI: 10.3389/fmicb.2023.1101544.
T cell receptor repertoire analysis in HTLV-1-associated diseases.
Clauze A, Enose-Akahata Y, Jacobson S
Front Immunol. 2022; 13:984274.
PMID: 36189294
PMC: 9520328.
DOI: 10.3389/fimmu.2022.984274.
MiR-150 in HTLV-1 infection and T-cell transformation.
DAgostino D, Raimondi V, Silic-Benussi M, Ciminale V
Front Immunol. 2022; 13:974088.
PMID: 36072598
PMC: 9442802.
DOI: 10.3389/fimmu.2022.974088.
Chitotriosidase 1 in the cerebrospinal fluid as a putative biomarker for HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) progression.
Gomes Y, Freitas N, Souza F, Sandim V, Pereira D, Nogueira F
Front Immunol. 2022; 13:949516.
PMID: 36052089
PMC: 9424492.
DOI: 10.3389/fimmu.2022.949516.
HTLV-1 intragenic viral enhancer influences immortalization phenotype , but is dispensable for persistence and disease development in animal models.
Maksimova V, Smith S, Seth J, Phelps C, Niewiesk S, Satou Y
Front Immunol. 2022; 13:954077.
PMID: 35958554
PMC: 9359075.
DOI: 10.3389/fimmu.2022.954077.
An Overview of Human T-Lymphotropic Virus Type 1 Lung Injury.
Dias A, Falcao L, Quaresma J
Front Immunol. 2022; 13:914498.
PMID: 35844492
PMC: 9285117.
DOI: 10.3389/fimmu.2022.914498.
Prevalence and Risk Factors for HTLV-1/2 Infection in Quilombo Remnant Communities Living in the Brazilian Amazon.
Dos Santos Brito W, Cardoso-Costa G, Roland Junior L, Pereira K, Lopes F, Santos B
Front Public Health. 2022; 10:871865.
PMID: 35433598
PMC: 9005874.
DOI: 10.3389/fpubh.2022.871865.